JP5261575B2 - 化学化合物 - Google Patents

化学化合物 Download PDF

Info

Publication number
JP5261575B2
JP5261575B2 JP2011515631A JP2011515631A JP5261575B2 JP 5261575 B2 JP5261575 B2 JP 5261575B2 JP 2011515631 A JP2011515631 A JP 2011515631A JP 2011515631 A JP2011515631 A JP 2011515631A JP 5261575 B2 JP5261575 B2 JP 5261575B2
Authority
JP
Japan
Prior art keywords
thiazolidine
dione
phenyl
methylidene
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011515631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526616A (ja
JP2011526616A5 (https=
Inventor
ダキン,レスリー
ダウリング,ジェームズ・エドワード
ラム,ミッチェル
リード,ジョン
スー,チビン
ツェン,シャオラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5261575(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2011526616A publication Critical patent/JP2011526616A/ja
Publication of JP2011526616A5 publication Critical patent/JP2011526616A5/ja
Application granted granted Critical
Publication of JP5261575B2 publication Critical patent/JP5261575B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2011515631A 2008-07-02 2009-07-02 化学化合物 Expired - Fee Related JP5261575B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7763908P 2008-07-02 2008-07-02
US61/077,639 2008-07-02
US18327809P 2009-06-02 2009-06-02
US61/183,278 2009-06-02
PCT/GB2009/050773 WO2010001169A2 (en) 2008-07-02 2009-07-02 Chemical compounds 251

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013031176A Division JP2013139459A (ja) 2008-07-02 2013-02-20 化学化合物

Publications (3)

Publication Number Publication Date
JP2011526616A JP2011526616A (ja) 2011-10-13
JP2011526616A5 JP2011526616A5 (https=) 2013-04-11
JP5261575B2 true JP5261575B2 (ja) 2013-08-14

Family

ID=41050276

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011515631A Expired - Fee Related JP5261575B2 (ja) 2008-07-02 2009-07-02 化学化合物
JP2013031176A Ceased JP2013139459A (ja) 2008-07-02 2013-02-20 化学化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013031176A Ceased JP2013139459A (ja) 2008-07-02 2013-02-20 化学化合物

Country Status (27)

Country Link
US (2) US8901307B2 (https=)
EP (1) EP2310010A2 (https=)
JP (2) JP5261575B2 (https=)
KR (1) KR20110031367A (https=)
CN (2) CN102137666B (https=)
AR (1) AR072791A1 (https=)
AU (1) AU2009265362B2 (https=)
BR (1) BRPI0914599A2 (https=)
CA (1) CA2729557A1 (https=)
CL (1) CL2010001636A1 (https=)
CO (1) CO6341555A2 (https=)
CR (1) CR20110016A (https=)
DO (1) DOP2010000408A (https=)
EA (1) EA018989B1 (https=)
EC (1) ECSP10010735A (https=)
HN (1) HN2010002786A (https=)
IL (1) IL210127A0 (https=)
MX (1) MX2010014233A (https=)
MY (1) MY155961A (https=)
NI (1) NI201100007A (https=)
NZ (1) NZ590859A (https=)
PE (1) PE20120304A1 (https=)
SV (1) SV2011003786A (https=)
TW (1) TWI461423B (https=)
UY (1) UY31952A (https=)
WO (1) WO2010001169A2 (https=)
ZA (1) ZA201100844B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013139459A (ja) * 2008-07-02 2013-07-18 Astrazeneca Ab 化学化合物

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013051672A1 (ja) * 2011-10-04 2013-04-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
MY158040A (en) * 2012-03-30 2016-08-30 Rohto Pharma Novel benzylidene azolidine derivative or salt thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
JP6378918B2 (ja) * 2013-04-03 2018-08-22 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とするPim阻害剤
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
TW201601769A (zh) * 2013-09-27 2016-01-16 樂敦製藥股份有限公司 皮膚外用組成物
WO2015046390A1 (ja) * 2013-09-27 2015-04-02 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
US20170145005A1 (en) * 2014-02-13 2017-05-25 The University Of Tokyo Kinase inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP5857104B2 (ja) * 2014-06-17 2016-02-10 ロート製薬株式会社 ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US10195189B2 (en) 2014-12-15 2019-02-05 Prosetta Antiviral, Inc. 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds
CN105985298B (zh) * 2015-02-10 2018-02-23 湖南大学 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
CN106032365B (zh) * 2015-03-11 2018-03-23 湖南大学 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
JP6969848B2 (ja) 2015-07-13 2021-11-24 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド プリナブリン組成物
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
WO2017176812A1 (en) 2016-04-05 2017-10-12 Immune Sensor, Llc cGAS ANTAGONIST COMPOUNDS
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2017216726A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
CA3067746A1 (en) * 2017-06-30 2019-01-03 The Regents Of The University Of California Compositions and methods for modulating hair growth
EP3706735A1 (en) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
JP7491510B2 (ja) * 2018-04-26 2024-05-28 メディシナル バイオコンバージェンス リサーチ センター mTOR阻害剤としての新規化合物及びその用途
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022006040A1 (en) 2020-06-30 2022-01-06 The Regents Of The University Of California Compositions and methods for modulating hair growth
WO2022086920A1 (en) * 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
CN116354901B (zh) * 2023-04-12 2024-04-26 郑州大学 一种噻唑烷二酮类化合物及其制备方法和应用
WO2025017207A1 (en) 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
CZ289317B6 (cs) 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
JP3668291B2 (ja) 1995-06-16 2005-07-06 久光製薬株式会社 新規なピペリジン誘導体
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20010099634A (ko) * 1999-07-01 2001-11-09 할리 켈빈 비. 텔로머라제 저해제 및 그 사용 방법
CN1155586C (zh) 1999-08-23 2004-06-30 杏林制药株式会社 取代的苄基噻唑烷-2,4-二酮衍生物
TW593293B (en) * 1999-08-23 2004-06-21 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives
WO2001034133A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP4782564B2 (ja) 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
US20050038098A1 (en) 2003-04-18 2005-02-17 Catherine Tachdjian Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
EP2217235A4 (en) * 2007-11-15 2011-01-12 Musc Found For Res Dev INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013139459A (ja) * 2008-07-02 2013-07-18 Astrazeneca Ab 化学化合物

Also Published As

Publication number Publication date
TW201004949A (en) 2010-02-01
CA2729557A1 (en) 2010-01-07
AU2009265362A1 (en) 2010-01-07
UY31952A (es) 2010-01-29
JP2011526616A (ja) 2011-10-13
ZA201100844B (en) 2011-10-26
CR20110016A (es) 2011-03-11
TWI461423B (zh) 2014-11-21
CL2010001636A1 (es) 2011-07-15
BRPI0914599A2 (pt) 2017-06-06
JP2013139459A (ja) 2013-07-18
WO2010001169A3 (en) 2010-08-05
EA018989B1 (ru) 2013-12-30
US20110218182A1 (en) 2011-09-08
KR20110031367A (ko) 2011-03-25
NZ590859A (en) 2012-08-31
DOP2010000408A (es) 2011-02-28
MY155961A (en) 2015-12-31
AR072791A1 (es) 2010-09-22
CO6341555A2 (es) 2011-11-21
PE20120304A1 (es) 2012-04-22
IL210127A0 (en) 2011-02-28
MX2010014233A (es) 2011-03-25
US20150051185A1 (en) 2015-02-19
EP2310010A2 (en) 2011-04-20
CN102137666A (zh) 2011-07-27
WO2010001169A2 (en) 2010-01-07
CN102137666B (zh) 2014-03-12
ECSP10010735A (es) 2011-01-31
US8901307B2 (en) 2014-12-02
SV2011003786A (es) 2011-05-13
HN2010002786A (es) 2013-01-28
CN103804371A (zh) 2014-05-21
AU2009265362B2 (en) 2012-07-19
EA201100119A1 (ru) 2011-08-30
NI201100007A (es) 2011-12-15

Similar Documents

Publication Publication Date Title
JP5261575B2 (ja) 化学化合物
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
ES2313991T3 (es) Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
CN101679401B (zh) 用于治疗肿瘤的作为met激酶抑制剂的2-氧代-3-苄基-苯并*唑-2-酮衍生物及相关化合物
KR102014478B1 (ko) 신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2015140133A1 (en) Piperidine-dione derivatives
CN102596923A (zh) 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
WO2016198374A1 (en) Aromatic sulfonamide derivatives
JP6559699B2 (ja) 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用
JP2012529513A (ja) トリアジン誘導体類及びそれらの治療応用
EP4188929B1 (en) Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof
EP3587411B1 (en) 1-(alpha-methylbenzyl)-5-(piperidinomethyl)imidazole derivatives and uses thereof for improving the pharmacokinetics of a drug
CA3134635A1 (en) Pyrrole compounds
WO2005103012A1 (ja) ヒドラジノ複素環ニトリル化合物およびその用途
JP7190755B2 (ja) オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
EA016300B1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
KR101457027B1 (ko) 트리아진 유도체와 이들의 치료적 용도
CN115109061B (zh) 三环化合物
EA046720B1 (ru) Соединения пиррола
KR20210048701A (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리디닐트리아진 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
HK40042713A (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
HK40042713B (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
HK1142333A (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors
BRPI0719333B1 (pt) Imidazotriazinas e imidazopirimidinas como inibidores de cinase, composição farmacêutica que as compreende e métodos in vitro

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130220

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20130220

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130426

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160502

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees